The National Health Insurance Administration (NHIA) said it plans to expand the coverage eligibility for receiving a third-generation targeted drug for lung cancer patients with the epidermal growth factor receptor (EGFR) starting next month.
The eligibility would be expanded to include people with stage 3b EGFR-mutated lung cancer, which is expected to benefit about 4,000 people, allowing them to save about NT$1.15 million (US$36,005) per year in medical expenses.
The expanded eligibility is expected to cost the NHI program between NT$4.1 billion and NT$5 billion per year, and with the annual expense of about NT$3.3 billion on eligible patients, the targeted drug would be the most expensive single type of drug in NHI history.
Photo: Chiu Chih-jou, Taipei Times
Lung adenocarcinoma is the most common type of lung cancer in Taiwan and KRAS mutations occur in about 20 to 40 percent of lung adenocarcinomas in Western populations, NHIA Director-General Shih Chung-liang (石崇良) said.
However, in Taiwan, KRAS mutations only occur in about 8 to 10 percent of patients with lung adenocarcinomas, while EGFR mutations occur in about 55 to 60 percent of patients with lung adenocarcinomas, he said.
The NHI program since April 2020 has conditionally covered a third-generation targeted drug called Tagrisso (osimertinib) for the treatment of EGFR-mutated lung cancer, but the eligibility was reduced in April 2022, which had caused an uproar among patients and medical professionals.
Studies published in international journals have suggested that compared with the first-generation targeted drug, the third-generation drug can reduce the risk of mortality by 20 percent.
With many calls for the NHI program to expand eligibility, Shih said the administration plans to expand the eligibility of Tagrisso from its current eligibility of stage 4 (metastasized) lung cancer to include stage 3b EGFR-mutated lung cancer with local invasiveness or metastases.
The Pharmaceutical Benefit and Reimbursement Scheme Joint Committee has approved the expanded eligibility, and it is scheduled to take effect on Oct. 1 at the earliest, he said.
About 3,400 people are treated with Tagrisso each year, which is an NHI expenditure of about NT$3.3 billion per year, NHIA statistics showed. After the eligibility expansion, it would increase the expenditure to more than NT$7 billion.
The total expenditure for NHI-covered medical treatment last year was more than NT$24.3 billion, the highest among all cancer types, and drug fees accounted for NT$12.2 billion, with a five-year average growth rate of 12.7 percent.
Regarding people with lung cancer without gene mutations that cannot receive the targeted drug, Shih said specialists have suggested including immunotherapy drugs for treating metastasized small cell lung cancer in NHI coverage, so there might be good news after the agency negotiates with drug companies.
An estimated 272 to 359 patients each year are expected to benefit from it, allowing them to save about NT$1.45 million per person per year, he added.
UPGRADE: The Kang Ding-class frigate is replacing its Chaparall missiles with Tien Chien II and Hua Yang VLS, which would provide it with long-range, 360° air defense Taiwan plans to produce 1,200 to 1,376 Hai Chien II missiles (海劍二, Sea Sword II) — also known as TC-2N — to serve as the standard air defense system of the navy’s surface combatant fleet, a source said yesterday. Last week, the Hai Chien II, the naval version of the Tien Kung II missile (天劍二, Sky Sword II), completed a live-fire test in waters off the National Chungshan Institute of Science and Technology’s Jiupeng facility (九鵬) in Pingtung County’s Manjhou Township (滿州). The MIM72 Chaparral and other dated air defense missiles that currently arm Taiwanese ships have inadequate range to combat Chinese
REASONS FOR TRAVEL: An assistant professor said that proposed amendments to penalize drivers if they used drugs overseas would not deter people from traveling People who operate a motor vehicle under the influence of marijuana would have their driver’s license revoked, even if they used the substance while overseas, the Ministry of Transportation and Communications said yesterday, citing proposed amendments to the Road Traffic Management and Penalty Act (道路交通管理處罰條例). The amendments would also authorize the government to revoke the licenses of people determined to have used Category 1 or Category 2 narcotics, even if they were not operating a vehicle while under the influence of drugs, as well as ban them from taking the license test for three years, the ministry said. People aged 18 or
HEAVY WEATHER: Typhoon Jangmi is due to crash straight into the Ryukyus as airlines look to shift flights to larger aircraft or cancel flights to Okinawa entirely Taiwan’s international air carriers announced flight adjustments over the weekend as Typhoon Jangmi is forecast to hit the Ryukyu Islands today and tomorrow. The Central Weather Administration (CWA) upgraded Jangmi from a tropical storm to a typhoon at 8am yesterday, with the eye located 580km south of Naha city. It was moving north at 19kph. Today, China Airlines’ CI-120, CI-121, CI-122 and CI-123 flights between Taoyuan and Naha, Okinawa, have been canceled as well as CI-132 and CI-133 between Kaohsiung and Naha. EVA Air’s BR-112, BR-113, BR-186 and BR-185 flights between Taoyuan and Naha are also canceled. Low-cost carrier Tigerair Taiwan canceled IT-230,
Johanne Liou (劉喬安), a Taiwanese woman who shot to unwanted fame during the Sunflower movement protests in 2014, returned to Taiwan last night after being deported from the US. She is to stand trial in Taiwan for charges involving embezzlement, fraud and drug crimes. The Criminal Investigation Bureau (CIB) said it took her into custody at Taiwan Taoyuan International Airport and would first question her before transferring her to the New Taipei District Prosecutors’ Office. She was arrested upon disembarking a flight from San Francisco that landed shortly before 7pm. Liou absconded to the US in 2019 after jumping bail
RSS